science

Retifanlimab

Retifanlimab is a science topic covered in the lgStudy science library. This page brings together a partial reference excerpt, illustrations, worked examples, real-world applications and a short study plan, so you can understand Retifanlimab rather than just read about it. In short: Retifanlimab, sold under the brand name Zynyz, is an anti-cancer medication used for the treatment of Merkel cell carcinoma. Retifanlimab is a programmed death receptor-1 (PD-1)–blocking monoclonal antibody.

Key takeaways

Retifanlimab belongs to science; place it in that map before memorising details.
Learn the definition first, then one example that makes the definition concrete.
Connect Retifanlimab to a quantity you can measure, compute or draw — that is where exam questions come from.
Reproduce the core statement of Retifanlimab from memory before moving on to harder problems.

Reference excerpt

Retifanlimab, sold under the brand name Zynyz, is an anti-cancer medication used for the treatment of Merkel cell carcinoma. Retifanlimab is a programmed death receptor-1 (PD-1)–blocking monoclonal antibody. It was approved for medical use in the United States in March 2023, and in the European Union in April 2024.

Medical uses Retifanlimab is indicated for the treatment of adults with metastatic or recurrent locally advanced Merkel cell carcinoma. In May 2025, the US Food and Drug Administration (FDA) expanded the indication for retifanlimab to include, when used with carboplatin and paclitaxel, the first-line treatment of adults with inoperable locally recurrent or metastatic squamous-cell carcinoma of the anal canal. The FDA also approved retifanlimab, as a single agent, for adults with locally recurrent or metastatic squamous-cell carcinoma of the anal canal with disease progression on or intolerance to platinum-based chemotherapy.

Adverse effects The US Food and Drug Administration (FDA) prescription label for retifanlimab includes warnings and precautions for severe and fatal immune-mediated adverse reactions, infusion-related reactions, complications of allogeneic HSCT, and embryo-fetal toxicity.

History The US Food and Drug Administration (FDA) evaluated the safety and efficacy of retifanlimab based on PODIUM-201 (NCT03599713), an open-label, multiregional, single-arm study evaluating 65 participants with metastatic or recurrent locally advanced MCC who had not received prior systemic therapy for advanced disease. The FDA granted the application for retifanlimab priority review, fast track, and orphan drug designations. The efficacy of retifanlimab with carboplatin and paclitaxel was evaluated in POD1UM-303/InterAACT 2 (NCT04472429), a randomized, multi-center, double-blind trial in 308 participants with chemotherapy-naïve inoperable locally recurrent or metastatic squamous-cell carcinoma of the anal canal. Participants received carboplatin AUC of 5 on day 1, and paclitaxel 80 mg/m2 on days 1, 8, and 15 for 6 cycles and were randomized (1:1) to receive either retifanlimab 500 mg intravenously every 4 weeks; or placebo intravenously every 4 weeks. The efficacy of retifanlimab as a single agent was evaluated in POD1UM-202 (NCT03597295), an open-label, multi-center, single-arm trial in 94 participants with locally recurrent or metastatic SCAC with disease progression on or intolerance to platinum-based chemotherapy. Participants received retifanlimab 500 mg intravenously every 4 weeks until disease progression, unacceptable toxicity, or up to 24 months.

Society and culture

Legal status In February 2024, the Committee for Medicinal Products for Human Use of the European Medicines Agency adopted a positive opinion, recommending the granting of a marketing authorization for the medicinal product Zynyz, intended for the treatment of Merkel cell carcinoma. The applicant for this medicinal product is Incyte Biosciences Distribution B.V. Retifanlimab was authorized for medical use in the European Union in April 2024.

Names Retifanlimab is the international nonproprietary name. Retifanlimab is sold under the brand name Zynyz.

References

External links Clinical trial number NCT03599713 for "A Study of INCMGA00012 in Metastatic Merkel Cell Carcinoma (POD1UM-201)" at ClinicalTrials.gov

Worked examples

Example 1 — a first encounter with Retifanlimab

Start with the simplest possible case. Write down what Retifanlimab claims or describes in one sentence, then invent the smallest concrete situation in which that sentence is true. In science, the smallest case is usually a single object, a single equation or a single measurement. Check that every symbol or term in your sentence has a meaning in that case.

Example 2 — changing one variable

Take the situation from Example 1 and change exactly one quantity: double it, halve it, or set it to zero. Predict what should happen to Retifanlimab before you calculate. Comparing your prediction with the result is the fastest way to find out whether you understand the idea or only the words.

Example 3 — an exam-style question

Typical questions about Retifanlimab ask you to (a) state it precisely, (b) apply it to given data, and (c) explain a limitation. Practise writing all three answers in under five minutes; the third part is what separates a full-mark answer from an average one.

Applications of Retifanlimab

In research: Retifanlimab appears in science research whenever the underlying quantities have to be modelled precisely. Papers usually cite it as a starting assumption and then explore where it breaks down.
In technology and industry: Engineering practice reuses Retifanlimab in design rules, simulations and safety margins. Knowing the idea lets you read a specification sheet and understand why the numbers look the way they do.
In the classroom: Retifanlimab is common in secondary-school and first-year university syllabi. It links to neighbouring topics Monoclonal antibodies for tumors, Orphan drugs, so understanding it makes those chapters shorter.
In everyday life: Look for Retifanlimab outside the textbook — in sport, cooking, traffic, electronics or the sky above you. An example you found yourself is remembered far longer than one you were given.

Ask Teacher Smith questions about this articleOpens your AI tutor with a question about “Retifanlimab” →

Affiliate

Preply — study more efficiently by working with a personal tutor. 50% off.

How to study Retifanlimab in 20 minutes

Read the reference excerpt below once, without taking notes.
Close the page and write down what Retifanlimab means in your own words.
Compare your version with the excerpt and mark what you missed.
Work through the three examples above with pen and paper.
Explain Retifanlimab out loud to somebody else — or to Teacher Smith in the lgStudy chat.

Frequently asked questions

What is Retifanlimab in simple terms?

Why does Retifanlimab matter?

Because it connects several science ideas at once: it gives you a definition you can apply, a quantity you can calculate, and a way to check whether a result is plausible.

How should I study Retifanlimab?

Read the excerpt, restate it from memory, then work through the examples and applications listed on this page. The five-step study plan above takes about twenty minutes.

What does this page cover?

It gives you a compact reference excerpt plus original lgStudy explanations, examples, applications and study material on Retifanlimab.